Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 80199 refers to a laboratory test specifically designed to measure the levels of tiagabine in the blood. Tiagabine, marketed under the brand name Gabitril, is classified as an anticonvulsant medication primarily utilized as an adjunctive treatment for individuals over the age of 12 who are experiencing partial seizure disorders. This medication plays a crucial role in managing seizures by modulating neurotransmitter activity in the brain. In addition to its primary use, tiagabine may also be prescribed off-label for various conditions, including anxiety disorders and neuropathic pain, highlighting its versatility in treating different neurological and psychological issues. To ensure effective therapeutic outcomes, it is essential to monitor tiagabine levels in patients. This monitoring is typically conducted through pre-dose (trough) blood draws, which are performed to assess the lowest concentration of the drug in the bloodstream before the next dose is administered. The blood sample required for this test is obtained through a venipuncture, a procedure that involves puncturing a vein to collect blood. The analysis of the blood sample is carried out using advanced techniques such as high-performance liquid chromatography coupled with tandem mass spectrometry, which allows for precise measurement of tiagabine concentrations in serum and/or plasma. This testing is vital for ensuring that patients maintain therapeutic levels of the medication, thereby optimizing treatment efficacy and minimizing potential side effects.
© Copyright 2026 Coding Ahead. All rights reserved.
The tiagabine level measurement is indicated for the following conditions:
The procedure for measuring tiagabine levels involves several key steps that ensure accurate and reliable results. First, a healthcare professional will perform a venipuncture, which is the process of puncturing a vein to collect a blood sample. This step is crucial as it provides the necessary specimen for testing. The blood sample is then collected in a suitable container, typically a serum or plasma tube, to prevent contamination and ensure the integrity of the sample. Once the blood sample is obtained, it is sent to a laboratory where it undergoes analysis. The testing method employed is high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). This advanced analytical technique allows for the precise quantification of tiagabine levels in the serum or plasma. The use of HPLC-MS/MS is essential due to its sensitivity and specificity, which are necessary for accurately measuring the low concentrations of tiagabine that may be present in the blood. After the analysis is complete, the results are compiled and reported back to the healthcare provider, who will interpret the tiagabine levels in the context of the patient's treatment plan. This information is vital for making informed decisions regarding dosage adjustments and overall management of the patient's condition.
Post-procedure care following the blood draw for tiagabine level measurement is generally minimal. Patients may experience slight discomfort or bruising at the venipuncture site, which typically resolves quickly. It is advisable for patients to keep the site clean and dry to prevent any potential infection. Once the results are available, healthcare providers will review the tiagabine levels to determine if they fall within the therapeutic range. If the levels are too low, an increase in dosage may be warranted; conversely, if the levels are too high, a reduction in dosage or a reevaluation of the treatment plan may be necessary. Continuous monitoring may be required to ensure that the patient maintains appropriate drug levels, particularly if there are changes in their condition or if they are taking other medications that could interact with tiagabine. Regular follow-up appointments will help in assessing the patient's response to treatment and making any necessary adjustments.
| Short Descr | DRUG SCREEN QUANT TIAGABINE | Medium Descr | DRUG SCREEN QUANTITATIVE TIAGABINE | Long Descr | Tiagabine | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2014-01-01 | Added | Added |
Get instant expert-level medical coding assistance.